Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Down 57.0% in September

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a significant decrease in short interest in September. As of September 15th, there was short interest totaling 43,900 shares, a decrease of 57.0% from the August 31st total of 102,200 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average daily volume of 4,120,000 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 4,120,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.5% of the company’s stock are short sold.

Institutional Trading of Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Birchview Capital LP bought a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned 1.32% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors own 8.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Zacks Research upgraded Aptevo Therapeutics to a “hold” rating in a report on Thursday, September 18th. Wall Street Zen raised Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, Roth Capital raised Aptevo Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy”.

Aptevo Therapeutics Price Performance

Shares of APVO opened at $1.45 on Friday. The business’s 50 day moving average is $1.91 and its 200 day moving average is $8.54. Aptevo Therapeutics has a 12-month low of $1.32 and a 12-month high of $381.10.

Aptevo Therapeutics (NASDAQ:APVO) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($8.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($83.20) by $74.80. As a group, sell-side analysts anticipate that Aptevo Therapeutics will post -15.84 earnings per share for the current fiscal year.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.